In vitro safety of ketotifen as a topical nasal rinse.
allergy immunotherapy
ciliary motility
immunotherapy
irrigations
therapeutics
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
02
05
2019
revised:
24
09
2019
accepted:
02
10
2019
entrez:
23
2
2020
pubmed:
23
2
2020
medline:
7
2
2021
Statut:
ppublish
Résumé
Ketotifen is a second-generation noncompetitive H1-antihistamine and mast-cell stabilizer. It is commonly used to treat or prevent allergic conjunctivitis, asthma, chronic urticaria, anaphylaxis, mast-cell, and other allergic-type disorders. However, it has never been studied in aspirin-exacerbated respiratory disease (AERD), an aggressive phenotype of chronic rhinosinusitis with nasal polyps, where the mast cell plays a prominent role its pathogenesis. Human sinonasal epithelial cells were grown at an air-liquid interface (ALI). Ketotifen powder was dissolved in saline to make 4 test solutions at 1.04, 2.08, 10.4, and 20.8 µg/mL. Control (saline) or ketotifen solution was added apically to ALI cultures from tissue of 5 unique patients, and ciliary beat frequency (CBF) changes were recorded. Lactate dehydrogenase was measured at 24 and 48 hours to estimate long-term cellular toxicity. Apical application of ketotifen at all concentrations was neither ciliotoxic nor ciliostimulatory, with no change in CBF over a period of 15 minutes after application. Cellular toxicity for all concentrations at 24 and 48 hours after application was <3% and <7%, respectively, that of lysed cultures. Topical application of ketotifen to an in vitro model of sinonasal epithelium is safe, as evaluated by CBF and lactate dehydrogenase. Ketotifen is neither ciliotoxic nor ciliostimulatory, and no long-term cellular toxicity was observed. Ketotifen may have promise as a topical nasal rinse in the treatment of AERD.
Sections du résumé
BACKGROUND
Ketotifen is a second-generation noncompetitive H1-antihistamine and mast-cell stabilizer. It is commonly used to treat or prevent allergic conjunctivitis, asthma, chronic urticaria, anaphylaxis, mast-cell, and other allergic-type disorders. However, it has never been studied in aspirin-exacerbated respiratory disease (AERD), an aggressive phenotype of chronic rhinosinusitis with nasal polyps, where the mast cell plays a prominent role its pathogenesis.
METHODS
Human sinonasal epithelial cells were grown at an air-liquid interface (ALI). Ketotifen powder was dissolved in saline to make 4 test solutions at 1.04, 2.08, 10.4, and 20.8 µg/mL. Control (saline) or ketotifen solution was added apically to ALI cultures from tissue of 5 unique patients, and ciliary beat frequency (CBF) changes were recorded. Lactate dehydrogenase was measured at 24 and 48 hours to estimate long-term cellular toxicity.
RESULTS
Apical application of ketotifen at all concentrations was neither ciliotoxic nor ciliostimulatory, with no change in CBF over a period of 15 minutes after application. Cellular toxicity for all concentrations at 24 and 48 hours after application was <3% and <7%, respectively, that of lysed cultures.
CONCLUSION
Topical application of ketotifen to an in vitro model of sinonasal epithelium is safe, as evaluated by CBF and lactate dehydrogenase. Ketotifen is neither ciliotoxic nor ciliostimulatory, and no long-term cellular toxicity was observed. Ketotifen may have promise as a topical nasal rinse in the treatment of AERD.
Substances chimiques
Anti-Allergic Agents
0
Histamine H1 Antagonists
0
L-Lactate Dehydrogenase
EC 1.1.1.27
Ketotifen
X49220T18G
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-270Subventions
Organisme : Foundation for the National Institutes of Health
ID : R01DC013588
Pays : International
Informations de copyright
© 2019 ARS-AAOA, LLC.
Références
Chang JE, White A, Simon RA, Stevenson DD. Aspirin-exacerbated respiratory disease: burden of disease. Allergy Asthma Proc. 2012;33:117-121.
Stevens WW, Schleimer RP. Aspirin-exacerbated respiratory disease as an endotype of chronic rhinosinusitis. Immunol Allergy Clin North Am. 2016;36:669-680.
Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135:676-681.e1.
Xu JJ, Sowerby L, Rotenberg BW. Aspirin desensitization for aspirin-exacerbated respiratory disease (Samter's triad): a systematic review of the literature. Int Forum Allergy Rhinol. 2013;3:915-920.
Adappa ND, Ranasinghe VJ, Trope M, et al. Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2018;8:49-53.
Adelman J, McLean C, Shaigany K, Krouse JH. The role of surgery in management of Samter's triad: a systematic review. Otolaryngol Head Neck Surg. 2016;155:220-237.
White A, Stevenson D. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012;33:588-594.
Steinke JW, Crouse CD, Bradley D, et al. Characterization of interleukin-4-stimulated nasal polyp fibroblasts. Am J Respir Cell Mol Biol. 2004;30:212-219.
Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease. J Allergy Clin Immunol. 2017;139:764-766.
Bosso JV, Schwartz LB, Stevenson DD. Tryptase and histamine release during aspirin-induced respiratory reactions. J Allergy Clin Immunol. 1991;88;830-837.
Baba A, Kazama I, Tachi M, et al. Anti-allergic drugs tranilast and ketotifen dose-dependently exert mast cell-stabilizing properties. Cell Physiol Biochem. 2016;38:15-27.
Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J Ocul Pharmacol Ther. 2003;19:75-81.
Németh A, Magyar P, Herceg R, Huszti Z. Potassium-induced histamine release from mast cells and its inhibition by ketotifen. Agents Actions. 1987;20:149-152.
Nurmatov UB, Rhatigan E, Simons FER, Sheikh A. H1-antihistamines for primary mast cell activation syndromes: a systematic review. Allergy. 2015;70:1052-1061.
Azuma H, Banno K, Yoshimura T. Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol. 1976;58:483-488.
Ben-Eli H, Solomon A. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy. Curr Opin Allergy Clin Immunol. 2018;18:411-416.
Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015;(6):CD009566.
Sokol KC, Amar NK, Starkey J, Grant JA. Ketotifen in the management of chronic urticaria: resurrection of an old drug. Ann Allergy Asthma Immunol. 2013;111:433-436.
Leonardi A, Capobianco D, Benedetti N, et al. Efficacy and tolerability of ketotifen in the treatment of seasonal allergic conjunctivitis: comparison between ketotifen 0.025% and 0.05% eye drops. Ocul Immunol Inflamm. October 2018:1-5. https://doi.org/10.1080/09273948.2018.1530363.
Martelli NA, Usandivaras G. Inhibition of aspirin-induced bronchoconstriction by sodium cromoglycate inhalation. Thorax. 1977;32:684-690.
Yoshida S, Amayasu H, Sakamoto H, et al. Cromolyn sodium prevents bronchoconstriction and urinary LTE4 excretion in aspirin-induced asthma. Ann Allergy Asthma Immunol. 1998;80:171-176.
Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs. 1990;40:412-448.
Boboridis KG, Kozeis N, Konstas AG. Revisiting ocular allergy: evaluating symptoms, benzalkonium chloride and efficacy of topical ketotifen 0.025%. Ocul Immunol Inflamm. February 2019:1-3. https://doi.org/10.1080/09273948.2018.1560478.
Workman AD, Cohen NA. The effect of drugs and other compounds on the ciliary beat frequency of human respiratory epithelium. Am J Rhinol Allergy. 2014;28:454-464.
Chiu AG, Chen B, Palmer JN, O'Malley BW, Cohen NA. Safety evaluation of sinus surfactant solution on respiratory cilia function. Int Forum Allergy Rhinol. 2011;1:280-283.
Tamashiro E, Banks CA, Chen B, et al. In vivo effects of citric acid/zwitterionic surfactant cleansing solution on rabbit sinus mucosa. Am J Rhinol Allergy. 2009;23:597-601.
Workman AD, Carey RM, Kohanski MA, Adappa ND, Palmer JN, Cohen NA. Effects of ophthalmologic solutions on sinonasal ciliated epithelium. Int Forum Allergy Rhinol. 2017;7:801-808.
Chen B, Antunes MB, Claire SE, et al. Reversal of chronic rhinosinusitis-associated sinonasal ciliary dysfunction. Am J Rhinol. 2007;21:346-353.
Lee RJ, Xiong G, Kofonow JM, et al. T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection. J Clin Invest. 2012;122:4145-4159.
Merkus FW, Verhoef JC, Schipper NG, Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29:13-38.
Sisson JH, Stoner JA, Ammons BA, Wyatt TA. All-digital image capture and whole-field analysis of ciliary beat frequency. J Microsc. 2003;211:103-111.
Zhao KQ, Cowan AT, Lee RJ, et al. Molecular modulation of airway epithelial ciliary response to sneezing. FASEB J. 2012;26:3178-3187.
Zhang L, Sanderson MJ. The role of cGMP in the regulation of rabbit airway ciliary beat frequency. J Physiol. 2003;551:765-776.
Zhang L, Han D, Song X, Wang H, Wang K, Liu Z. Effects of ephedrine on human nasal ciliary beat frequency. ORL J Otorhinolaryngol Relat Spec. 2008;70:91-96.
Zhou H, Wang X, Brighton L, Hazucha M, Jaspers I, Carson JL. Increased nasal epithelial ciliary beat frequency associated with lifestyle tobacco smoke exposure. Inhal Toxicol. 2009;21:875-881.
Hilding AC. The role of the respiratory mucosa in health and disease. Minn Med. 1967;50:915-919.
DelGaudio JM, Wise SK. Topical steroid drops for the treatment of sinus ostia stenosis in the postoperative period. Am J Rhinol. 2006;20:563-567.
Rudmik L, Smith TL. Evidence-based practice: postoperative care in endoscopic sinus surgery. Otolaryngol Clin North Am. 2012;45:1019-1032.
Workman AD, Carey RM, Kohanski MA, et al. Relative susceptibility of airway organisms to antimicrobial effects of nitric oxide. Int Forum Allergy Rhinol. 2017;7:770-776.
Verhoef JC, Merkus F. Nasal Absorption Enhancement: Relevance to Nasal Drug Delivery. Drug Absorption Enhancement, Concept, Possibilities, Limitations and Trends. Chur, Switzerland: Harwood-Academic Publishers; 1994.
Cohen NA. Sinonasal mucociliary clearance in health and disease. Ann Otol Rhinol Laryngol Suppl. 2006;196:20-26.
van de Donk HJ, van den Heuvel AG, Zuidema J, Merkus FW. The effects of nasal drops and their additives on human nasal mucociliary clearance. Rhinology. 1982;20(3):127-137.
Verret DJ, Marple BF. Effect of topical nasal steroid sprays on nasal mucosa and ciliary function. Curr Opin Otolaryngol Head Neck Surg. 2005;13:14-18.
Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg. 2004;130:131-141.
Corbo GM, Foresi A, Bonfitto P, Mugnano A, Agabiti N, Cole PJ. Measurement of nasal mucociliary clearance. Arch Dis Child. 1989;64:546-550.
Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev. 1998;29:39-49.
Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control Release. 2003;87:187-198.